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Abstract
The objective of this work was to identify genes involved in
impaired angiogenesis by comparing the transcriptosomes of
microvascular endothelial cells from normal subjects and
patients affected by systemic sclerosis (SSc), as a unique
human model disease characterized by insufficient
angiogenesis. Total RNAs, prepared from skin endothelial cells
of clinically healthy subjects and SSc patients affected by the
diffuse form of the disease, were pooled, labeled with
fluorochromes, and hybridized to 14,000 70 mer
oligonucleotide microarrays. Genes were analyzed based on
gene expression levels and categorized into different functional
groups based on the description of the Gene Ontology (GO)
consortium to identify statistically significant terms. Quantitative
PCR was used to validate the array results. After data
processing and application of the filtering criteria, the analyzable
features numbered 6,724. About 3% of analyzable transcripts
(199) were differentially expressed, 141 more abundantly and
58 less abundantly in SSc endothelial cells. Surprisingly, SSc
endothelial cells over-express pro-angiogenic transcripts, but
also show up-regulation of genes exerting a powerful negative
control, and down-regulation of genes critical to cell migration
and extracellular matrix-cytoskeleton coupling, all alterations that
provide an impediment to correct angiogenesis. We also
identified transcripts controlling haemostasis, inflammation,
stimulus transduction, transcription, protein synthesis, and
genome organization. An up-regulation of transcripts related to
protein degradation and ubiquitination was observed in SSc
endothelial cells. We have validated data on the main anti-
angiogenesis-related genes by RT-PCR, western blotting, in
vitro  angiogenesis and immunohistochemistry. These
observations indicate that microvascular endothelial cells of
patients with SSc show abnormalities in a variety of genes that
are able to account for defective angiogenesis.
Introduction
Systemic sclerosis (SSc) affects the connective tissue of the
skin and internal organs, such as gastrointestinal tract, lungs,
heart and kidneys. Disease progression involves the immune
system, extracellular matrix (ECM) deposition and the microv-
asculature [1]. In the later stages of the disease, the vessel
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walls are thickened and hyalinized and their lumen is narrowed,
leading to devascularization and tissue ischemia, which is not
counterbalanced by active neo-angiogenesis. Angiogenesis,
the process of new blood vessel generation from capillary or
post-capillary venules, requires gross changes in endothelial
cell function. In this process, an endothelial cell modifies the
interaction with its basement membrane, remodels and
migrates through ECM, proliferates, and differentiates. The
final effect is the formation of endothelial tubules with a lumen,
which are capable of transporting blood [2]. Newly expressed
molecules or hyper-expression of pre-existing ones are coordi-
nately required in this series of events, including proteolytic
enzymes that are believed to be critical to ECM remodeling
[3], growth factor activation [4] and release of ECM-trapped
regulatory molecules [5,6].
While gene-expression profiling using microarray technologies
is available for skin biopsies [7] and cultured fibroblasts from
individuals with a diagnosis of SSc [8,9], a global portrait of
gene expression of microvascular endothelial cells (MVECs)
has not been reported in the literature. In order to better under-
stand whether dysregulated genes may contribute to the
pathogenesis of defective angiogenesis, we have undertaken
studies of gene expression in MVECs isolated from the
lesional skin of patients affected by the diffuse form of SSc
and matched healthy controls, using a 14,000 oligonucleotide
(70 mer) microarray. After the identification of differentially
expressed genes by a Bayesian empirical model [10,11],
genes were annotated on the basis of biological process
ontology and statistically significant gene ontology terms were
evaluated.
The results show that of the several thousands genes that
passed filtering criteria, 199 genes are differentially
expressed, 141 being up-regulated and 58 down-regulated in
SSc endothelial cells. We observed that SSc endothelial cells
overexpress pro-angiogenic and anti-angiogenic transcripts,
and down-regulation of genes critical to cell migration and pro-
liferation (including tissue kallikreins (KLKs)) [12], adhesion
and capillary differentiation. We have validated the data on the
main anti-angiogenesis-related molecules by RT-PCR and
have focused functional experiments on differentially
expressed molecules that have recently been shown to be rel-
evant to endothelial cell physiology, such as plexin B1,
pent(r)axin 3 and desmoglein (DSG) 2. Plexin B1, which we
found to be down-regulated in MVECs of SSc patients, has
been reported to bind and mediate the pro-angiogenic signal
of semaphorin 4D [13]. Pent(r)axin 3, which we found to be
up-regulated in MVECs of SSc patients, inhibits the pro-ang-
iogenic effect of Fibroblast Growth Factor-2 (FGF2), including
that produced by autocriny of endothelial cells [14]. Desmo-
glein 2 is a calcium-binding trans-membrane protein of the
cadherin cell adhesion molecule superfamily that mediates
homophilic cell adhesion, and has been identified as a struc-
tural component of endothelial cell intercellular junctions [15].
Here we show that DSG2 down-regulation in MVECs of SSc
subjects associates with an anti-angiogenic phenotype.
We also identified differential expression of transcripts con-
trolling haemostasis, inflammation, stimulus transduction, tran-
scription, protein synthesis and genome organization. Other
up-regulated genes are markers of cellular stress, such as
those of the ubiquitin-proteasoma family. Taken together, our
results show that over-expression of some genes in SSc
MVECs indicates a response to a powerful pro-angiogenic
environment, while over-expression of others may render them
unable to respond to angiogenic stimuli by over-expression of
anti-angiogenic and hypo-expression of pro-angiogenic mole-
cules.
Materials and methods
Patients, controls, tissue biopsies and endothelial cell 
preparation
Patients with diffuse SSc (submitted to skin biopsies for diag-
nostic purposes at the Departments of Medicine, Division of
Rheumatology, Florence and Pisa Universities) and healthy
controls were used as sources of MVECs. All patients (20
females and 10 males, with a mean disease duration of 9 years
(range 3.1 to 12)) fulfilled the American College of Rheumatol-
ogy criteria for the classification of SSc [16]. Only patients
classified as having the diffuse cutaneous SSc were admitted
to the study (sclerosis of both distal and proximal extremities,
with or without truncal involvement). Patients with overlap
symptoms to other connective diseases were excluded from
the study, as well as patients affected by other diseases involv-
ing the vascular system. Biopsies were performed on the dor-
sal involved skin of the hands. Fifteen healthy patients
undergoing surgery for traumatic events involving the hands
were subjected to the MVEC isolation procedure, after punch
biopsies of the dorsal skin of the hands, which were proc-
essed as skin biopsies of SSc patients. The study was
approved by the local Ethical Committee and patient consent
was obtained from each subject enrolled. Ethics approval and
patient consent were granted for this manuscript.
The patients were not on steroids, cyclophosphamide, D-pen-
icillamine, relaxin or other disease-modifying drugs. Calcium
channel blockers were stopped ten days before the biopsy.
Only proton pump inhibitors and cisapride were allowed.
Briefly, skin biopsies have been mechanically cleaned of epi-
dermis and adipose tissue in order to obtain a pure specimen
of vascularized dermis, and treated as described elsewhere
[17,18]. In some cases, clusters of round-shaped cells were
squeezed from microvessels and formed colonies composed
by polygonal elements. Such colonies were detached with
EDTA, and CD31-positive cells were subjected to immuno-
magnetic isolation with Dynabeads CD31 (Dynal ASA, Oslo,
Norway) [18]. Isolated cells were further identified as MVECs
by labeling with anti-factor VIII-related antigen and by re-prob-
ing with anti-CD31 antibodies. Cells were maintained in com-Available online http://arthritis-research.com/content/8/4/R115
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plete MCDB medium, supplemented with 30% FCS, 20 µg/ml
endothelial cell growth supplement (ECGS), 10 µg/ml hydro-
cortisone, 15 UI/ml heparin, and antibiotics (100 UI/ml penicil-
lin, 100 µg/ml streptomycin, 50 µg/ml amphotericin). MVECs
from normal individuals and from SSc patients are referred to
as N-MVECs and SSc-MVECs, respectively, and were used
between the third and seventh passage in culture. A biopsy
specimen from each subject was formalin fixed and paraffin
embedded for immunohistochemistry assays. Each case has
been stained with hematoxilin and eosin to assess the original
diagnosis.
RNA preparation
Since the success rate for isolation of SSc-MVECs is lower
than 20%, compared to a success rate of more than 50% for
N-MVEC, controls were matched by age and sex to the SSc
cases that yielded MVECs. Therefore, total RNA was prepared
from six N-MVEC and six SSc-MVEC pellets using the RNeasy
Minikit (Qiagen, Hilden, Germany) according to the manufac-
turer's protocol. Equal quantities of total RNA from each of the
six N-MVEC and six SSc-MVEC pellets were pooled to give a
N-MVEC pool and a SSc-MVEC pool.
Microarray based gene expression analysis
The setting and the subsequent hybridization of microarrays
were performed as described in a previous paper [12]. Briefly,
we used poly-L-lysine (Sigma Chemical Company, St. Louis,
MO, USA) coated arrays representing 14,000 genes (70 mer
oligonucleotides; Human Array-Ready Oligo set version 1.1,
Operon Technologies, Inc., Alameda, CA, USA). We reverse
transcribed and labeled 20 µg of the N-MVEC pool and 20 µg
of the SSc-MVEC pool with NHS-cyanine dyes (Cy3 and Cy5;
Amersham Biosciences, Amersham Place, England). The two
labeled probes were hybridized with the array for 16 h at 65°C.
Arrays were scanned by using a 4000B Scanner (Axon Instru-
ments, Union City, CA, USA). Due to difficulty in growing SSc-
MVECs, we performed two replicates of the microarray exper-
iment: one with N-MVECs Cy3 labeled and SSc-MVECs Cy5
labeled and one with N-MVECs Cy5 labeled and SSc-MVECs
Cy3 labeled (dye swap).
Image processing and statistical analysis
Each hybridization produced a pair of 16-bit images, which
were processed using the GenePix Pro 4.1 software (Axon
Instruments). Poorly spotted genes, expressing weak or dis-
torted signals, were automatically discarded by the GenePix
Pro 4.1 software and manually by visual inspection. In order to
reduce the identification of false positive differentially
expressed genes, spots exhibiting at the same time low Cy3
and Cy5 fluorescent signal intensities (<100) were discarded
from consideration by pre-processing the raw data in Axon
.gpr format using Microsoft Excel. For each microarray, we per-
formed a local intensity-dependent normalization using an low-
ess scatter plot smoother to remove dye and spatial (print-tip)
effects [19]. After single-slide normalization we applied a dye-
swap normalization as proposed by Kerr and colleagues
[11,20] to correct the different properties of the dyes on a
gene by gene basis [21]. The data obtained from normalization
was analyzed by Newton algorithm [10]. More details on
image processing and statistical analysis have been previously
reported [12]. The full data set is available at ArrayExpress
[22].
Gene ontology data analysis
In our study we used one of the three ontologies produced by
the Gene Ontology (GO) consortium, the biological process
ontology. The term 'biological process' should be interpreted
as a biological function to which the gene product contributes.
The actual mappings of genes to GO terms are provided by
the Gene Ontology Annotation Database [23,24]. The map-
pings were downloaded from [25].
In brief, given a set of genes and one ontology, we first found
the set of all unique GO terms within the ontology that are
associated with one or more of the genes of interest. Next, we
determined how many of the selected 199 differentially
expressed genes are annotated at each term and how many of
the genes that were assayed (all the genes represented on the
microarray) are annotated at the term. The test evaluated if
there are more interesting genes at the term than one might
expect by chance. Due to the small number of genes in some
categories, significant terms were inferred by two-sided
Fisher's exact test [26]. The statistical analyses were imple-
mented in the R environment using Bioconductor packages
[27].
Criteria based only on GO terms were not sufficient to classify
a gene as positively or negatively involved in the regulation of
angiogenesis. Therefore, we included the biological proc-
esses obtained by GO into the following families: angiogen-
esis, apoptosis, haemostasis, inflammation and immunity,
stress and ubiquitination, transductions, DNA/RNA organiza-
tion, transcription, protein synthesis, and mitochondrial func-
tions. In particular, in order to be classified as pro-angiogenic,
a gene must play a significant role in endothelial cell adhesion,
invasion, proliferation, and differentiation.
Real Time RT-PCR based gene expression analysis
In order to confirm results obtained by microarray analysis, the
expression patterns of nine selected genes were also meas-
ured by reverse transcription (RT)-PCR. For RT-PCR, 7 µg of
the total RNA pools used for comparative microarray experi-
ments were reverse-transcribed using M-MLV transcriptase
(Gibco BRL, Gaithersburg, MD, USA) and random hexamer
primers (Amersham). To quantify the transcribed IL8, PLAU,
KLK9, KLK11, KLK12, PTX3, PLXNB1, DSG2, and CTGF
genes, we performed TaqMan RT-PCR (Applied Biosystems,
Foster City, CA, USA) on an ABI Prism 7700 instrument. VIC-
labeled human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; #4326317E) and FAM-labeled human IL8Arthritis Research & Therapy    Vol 8 No 4    Giusti et al.
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(#Hs00174103_m1), urokinase type plasminogen activator
(PLAU; #Hs00705898_s1) KLK9 (#Hs00705898_s1),
KLK11 (#Hs00170182_m1 and Hs00374668_m1), KLK12
(#Hs00377603_m1), PTX3 (#Hs00173615_m1), PLXNB1
(#Hs00182227_m1), DSG2 (#Hs00170071_m1), and con-
nective tissue growth factor (CTGF; #Hs00170014_m1) Taq-
Man pre-developed assays (Applied Biosystems, Foster City,
CA, USA) were used. Expression of IL8, PLAU, KLKs, PTX3,
PLXNB1, DSG2, and CTGF genes was normalized to
GAPDH and displayed as fold-change relative to N-MVEC
RNA used as the calibrator. Reactions were performed in
duplicate with 200 ng cDNA. The experiment was repeated in
two independent runs. ∆Ct values of the samples were deter-
mined by subtracting the average of the duplicate Ct values of
the target genes from the average of the duplicate Ct values
of the GAPDH gene (reference). The relative gene expression
levels were determined by subtracting the average ∆Ct value
of the target from the average ∆Ct value of the calibrator. The
amount of target (expressed as fold change), normalized to an
endogenous reference and relative to a calibrator, was given
by 2-∆∆Ct. Moreover, for all the genes reported in Table 1, 7 µg
of total RNA from MVECs from the six individual SSc patients
and the six healthy subjects was reverse-transcribed and ana-
lyzed.
Immunohistochemistry
For immunohistochemistry, tissue sections were 3 to 5 µm
thick and placed on pretreated glass slides, dewaxed and
treated to block endogenous peroxidase activity. The following
primary antibodies were employed: rabbit anti-human KLK9
(catalog n K005-12, raised against a synthetic peptide corre-
sponding to amino acids 239 to 250 of the human KLK9 pro-
tein) and anti-human KLK12 (catalog n K005-15, raised
against a synthetic peptide corresponding to amino acids
236–248 of the human KLK12 protein), and mouse anti-
human KLK11 (catalog n K005-14, raised against human
recombinant KLK11), all from US Biological (Swampscott,
MA, USA); anti-DSG mouse monoclonal antibody (Chemicon,
Temecula, CA, USA); anti-pentraxin 3 rat monoclonal antibody
MNB4 (Alexis Biochemical, Lausen, Switzerland); anti-plexin
B1 and anti-CTGF rabbit polyclonal antibodies, both from
Santa Cruz Biotechnology (Santa Cruz, CA, USA); murine
monoclonal antibody 5B4 (mAb5B4), which recognizes the
kringle domain of the A chain of PLAU, a kind gift of Dr ML Nolli
(Lepetit Research Center, Varese, Italy); and anti-IL8 rabbit
polyclonal antibodies (Chemicon, Temecula, CA, USA). All the
primary antibodies were diluted 1:40 and incubated overnight
with tissue sections in a moist chamber at 4°C. A standard
streptavidin-biotin detection system (Vector, Burlingame, CA,
USA) was carried out. Isotype Ig controls were used in parallel
with primary antibodies to assess the specificity of the stain-
ing. Primary antibody bound to antigen was visualized by
diaminobenzidine staining and a nuclear counterstaining with
hematoxilin was performed. Immunohistochemistry was per-
formed on the skin biopsies of the six normal subjects and six
SSc patients whose MVECs were used for RNA preparation.
Immunohistochemistry quantification was performed by image
analysis using the ScnImage program [28].
Western blotting
N-MVECs and SSc-MVECs were grown to 70% confluence
and serum-starved overnight in MCDB supplemented with 2%
FCS. Cells were then suspended in lysis buffer (10 mM Tris-
HCl, pH 7.4, containing 150 mM NaCl, 1% Triton X-100, 15%
glycerol, 1 mM sodium orthovanadate, 1 mM NaF, 1 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, and 10 µg/ml
aprotinin). We electrophoresed 60 µg of the cell extract pro-
teins on 12% SDS-PAGE under reducing conditions and then
blotted to a polyvinylidene difluoride membrane (Hybond-C
Extra; Amersham Biosciences, Piscataway, NJ, USA) for 3 h at
35 V. The membrane was incubated with 5% skim milk in 20
mM Tris buffer, pH 7.4, for 1 h at room temperature to block
Table 1
Time-fold up- or down-expression of genes analyzed by real time PCR in SSc-MVECs versus N-MVECs
Gene name Time-fold up- or down-expression in SSc-MVECs relative to N-MVECs
KLK9 10.63 (8.26–13.67) ↓
KLK11 53.07 (41.44–67.98) ↓
KLK12 19.02 (11.61–31.17) ↓
PLXNB1 1.90 (1.41–2.13) ↓
DSG2 35.08 (28.23–43.73) ↓
IL8 2.85 (1.82–4.37) ↑
PLAU 2.44 (1.48–3.65) ↑
PTX3 1.58 (1.29–1.87) ↑
CTGF 1.42 (1.34–1.52) ↑
Upward and downward arrows mean up-regulation and down-regulation in microvascular endothelial cells from patients with systemic sclerosis 
(SSc-MVECs), respectively. N-MVECs, microvascular endothelial cells from normal subjects.Available online http://arthritis-research.com/content/8/4/R115
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Table 2
List of all the Gene Ontology significant terms with more than two annotated genes on the array (N > 2)
GO category number GO term P value n/N Genes
6412 Protein biosynthesis <0.001 15/205 EIF4G1(↑), ITGB4BP(↑), LAMR1(↑), 
RPL7(↑), RPL9(↑), RPL10(↑), 
RPL12(↑), RPL23A(↑), RPS5(↑), 
RPS10(↑), RPS20(↑), RPL14(↑), 
NOLA2(↑), RPL10A(↑), RPL38(↑)
50930 Induction of positive 
chemotaxis
0.002 2/4 AZU1(↓), IL8(↑)
6878 Copper ion homeostasis 0.002 2/4 ATOX1(↑), MT2A(↑)
6337 Nucleosome disassembly 0.002 2/4 HMGA1(↑), SUPT16H(↑)
6508 Proteolysis and peptidolysis 0.002 13/290 ANPEP(↑), AZU1(↓), CAPN2(↑), 
NEDD8(↑), PLAT(↑), PLAU, PRSS1(↓), 
ADAM15(↑), NPEPPS(↑), KLK11(↓), 
SUPT16H(↑), CASP14(↓), KLK12(↓)
7266 Rho protein signal 
transduction
0.004 3/18 RHOA(↑), ARHGDIB(↑), CFL1(↑)
1516 Prostaglandin biosynthesis 0.008 2/8 MIF(↑), PTGDS(↓)
30036 Actin cytoskeleton 
organization and biogenesis
0.010 4/47 RHOA(↑), ARHGDIB(↑), CFL1(↑), 
PFN1(↑)
42157 Lipoprotein metabolism 0.011 2/9 APOA1(↓), HMGA1(↑)
6928 Cell motility 0.012 6/104 ACTN4(↑), CTGF(↑), IL8(↑), 
SPOCK(↑), ACTR3(↑), ARPC2(↑)
43065 Positive regulation of 
apoptosis
0.013 2/10 BCL2L11(↓), MTCH1(↑)
6445 Regulation of translation 0.014 3/28 MKNK2(↑), LAMR1(↑), PPP2CA(↑)
43066 Negative regulation of 
apoptosis
0.016 2/11 MIF(↑), ANGPTL4(↑)
30155 Regulation of cell adhesion 0.019 2/12 IL8(↑), PPP2CA(↑)
6979 Response to oxidative stress 0.024 3/34 ATOX1(↑), DUSP1(↑), GPX2(↓)
7596 Blood coagulation 0.026 4/61 GP9(↓), PLAT(↑), PLAU(↑), THBD(↑)
6869 Lipid transport 0.026 3/35 APOA1(↓), HMGA1(↑), LBP(↓)
9611 Response to wounding 0.030 2/15 CTGF(↑), MDK(↑)
6355 Regulation of transcription, 
DNA-dependent
0.037 11/1,042 BTF3L3(↑), RUNX2(↓), ENO1(↓), 
GATA6(↓), HMGA1(↓), FOXA2(↓), 
NFKB2(↓), SSRP1(↑), UBE2V1(↑), 
NFAT5(↓), SIX4(↓)
45941 Positive regulation of 
transcription
0.047 2/19 GATA6(↓), HMGA1(↑)
7243 Protein kinase cascade 0.047 3/44 MKNK2(↑), STK17A(↓), MAP4K1(↓)
7605 Perception of sound 0.048 4/74 GJA1(↑), PMP22(↑), WDR1(↑), 
TIMM8B(↑)
P values were determined by Fisher's exact test. Genes is a list of differentially expressed genes annotated to the GO terms; upward and 
downward arrows indicate up- and down-regulation, respectively. GO, gene ontology; n, number of differentially expressed genes annotated to 
the GO term; N, number of genes represented on the array annotated to the GO term;Arthritis Research & Therapy    Vol 8 No 4    Giusti et al.
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non-specific binding and then probed with antibodies directed
against pentraxin 3, or plexin B1 or DSG2 overnight at 4°C.
After incubation with horseradish peroxidase-conjugated don-
key anti-mouse IgG (1:5,000) for 1 h (Amersham Bio-
sciences), immune complexes were detected with the
enhanced chemiluminescence detection system (Amersham
Biosciences). The membranes were exposed to autoradio-
graphic films (Hyperfilm MP; Amersham Biosciences) for 1 to
30 minutes.
Migration assays
A Boyden chamber was used to evaluate spontaneous and
stimulated invasion (chemoinvasion) through Matrigel-coated
porous filters, as described [12]. For spontaneous invasion,
50 µl of cell suspension (6.25 × 103 cells) were placed in the
upper compartment of the chamber and migration was
allowed to occur for 6 h. To inhibit the activity of the relevant
molecules, specific antibodies (anti-pentraxin 3 and anti-plexin
B1, each at 3 µg/ml final concentration) were added to both
the upper and lower compartment of the migration chamber.
Irrelevant mouse IgGs were used to verify the specificity of the
effect. The number of cells moving across the filter measured
mobilization. Experiments were performed in triplicate. Migra-
tion was expressed as mean ± standard deviation (SD) of the
number of total cells counted per filter or as the percentage of
basal response.
Preparation of SSc-MVEC conditioned medium
Confluent cultures of SSc-MVECs were washed twice with
phosphate-buffered saline and incubated overnight in the
presence of MCDB medium supplemented with 2% FCS. The
culture supernatant was centrifuged at 1,500 rpm for 10 min-
utes and either used immediately or stored at -20°C.
In vitro capillary morphogenesis assay
Matrigel (0.5 ml; 10 to 12 mg/ml) was pipetted into 13 mm
diameter tissue culture wells and polymerized for 30 minutes
to 1 h at 37°C, as described [12]. N-MVECs were plated (60
× 103/ml) in complete MCDB medium supplemented with
30% FCS and 20 µg/ml endothelial cell growth supplement.
Capillary morphogenesis was also performed in the presence
of 3 µg/ml of anti-pentraxin 3 or anti-plexin B1 antibody. Irrele-
vant mouse IgGs were used as negative control. Plates were
photographed at 24 h. Results were quantified by measuring
the percentage of the photographic field occupied by
endothelial cells by image analysis. Six to nine photographic
fields from three plates were scanned for each point.
Statistical analysis
Results are expressed as means ± SD for (n) experiments.
Multiple comparisons were performed by the Student-New-
man-Keuls test, after demonstration of significant differences
among medians by nonparametric variance analysis according
to Kruskal-Wallis.
Results
Microarray, gene ontology analysis, and class 
distribution of differentially expressed genes
Of the 14,000 transcripts represented on our arrays, after data
processing and application of the filtering criteria, the analyza-
ble features numbered 6,724. The full list of the 150 most
expressed genes, independent of the cellular source (N-
MVEC and SSc-MVEC), is available as Additional file 1a. We
used a Newton algorithm after single slide and dye-swap nor-
malization to assess the 6,724 genes expressed by MVECs for
differential expression between SSc-MVECs and N-MVECs.
Genes found differentially expressed between SSc-MVECs
and N-MVECs numbered 199 (3% of the total transcripts ana-
lyzed; Additional files 2 to 7). Of these, 141 transcripts were
expressed more abundantly and 58 less abundantly in the
SSc-MVECs.
To analyze the involvement of differentially expressed genes in
different biological functional groups, all the genes present on
the microarray were annotated for their biological processes.
According to GO analysis, we observed 55 significant terms
(P value <0.05) associated with genes differentially expressed
in SSc (Table 2). In Table 2, significant terms with more than
two annotated genes (N) on the array are reported; also, for
each significant GO term, the symbols of the genes are
reported. The full list of GO terms for all the differentially
expressed genes is available in Additional file 1b.
The GO biological processes include many of those known to
be required to fulfill an angiogenic program. Of particular inter-
est are the genes involved in proteolysis and peptidolysis, cell
migration and cell motility, Rho protein signal transduction,
regulation of cell adhesion, blood coagulation, and mitosis.
However, many of the differentially expressed genes have mul-
tiple functions, each one often required for angiogenesis, and
some recognized pro- or anti-angiogenic properties of several
genes are not yet available in the GO biological processes.
Because of this, we decided to further classify the differentially
expressed genes according to a series of criteria that take into
consideration a recognized role of the relevant encoded pro-
tein in the biological processes shown in Table 3: angiogen-
esis (Table 3 and Additional file 2), including cell invasion,
proliferation, adhesion, differentiation, and inhibition of angio-
genesis; apoptosis, haemostasis, inflammation and immunity
(Table 3 and Additional file 3); cellular stress and ubiquitina-
tion (Table 3 and Additional file 4); transductions, DNA/RNA
organization, and regulation of transcription (Table 3 and Addi-
tional file 5); and regulation of protein synthesis and mitochon-
drial functions (Additional file 6). Each gene endowed with
multiple functions is mentioned in more than a single additional
file.Available online http://arthritis-research.com/content/8/4/R115
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Table 3
Class distribution of differentially expressed genes with a log odds ratio >1
Gene symbol Gene title M
Angiogenesis
MT1A ↑ Metallothionein 1A 3.25
PLAT ↑ Plasminogen activator, tissue 2.23
ANGPTL4 ↑ Angiopoietin-like 4 1.97
CTGF ↑ Connective tissue growth factor 1.80
ENO1 ↑ Enolase 1 1.67
PTX3 ↑ Pentaxin-related gene, rapidly induced by IL-1 beta 1.66
VCL ↑ Vinculin 1.65
LAMR1 ↑ Laminin receptor 1 1.63
PFN1 ↑ Profilin 1 1.54
MT2A ↑ Metallothionein 2A 1.50
SPOCK ↑ Sparc/osteonectin (testican) 1.46
MT1E ↑ Metallothionein 1E 1.43
CCND1 ↑ Cyclin D1 1.40
CFL1 ↑ Cofilin 1 1.31
CAPN2 ↑ Calpain 2, large subunit 1.28
MIF ↑ Macrophage migration inhibitory factor 1.24
WDR1 ↑ WD repeat domain 1 1.21
IL8 ↑ IL8 1.18
CLSTN1 ↑ Calsyntenin 1 1.07
ADAM15 ↑ A disintegrin and metalloproteinase domain 15 1.06
EFEMP1 ↑ EGF-containing fibulin-like extracellular matrix protein 1 1.03
KLK9 ↓ Kallikrein 9 -1.23
PLXNB1 ↓ Plexin B1 -1.19
KLK12 ↓ Kallikrein 12 -1.08
KLK11 ↓ Kallikrein 11 -1.08
DSG2 ↓ Desmoglein 2 -1.04
Apoptosis
TNFRSF6B ↑ Tumor necrosis factor receptor superfamily, member 6b, 
decoy
2.20
PRG1 ↑ Proteoglycan 1, secretory granule 1.32Arthritis Research & Therapy    Vol 8 No 4    Giusti et al.
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CFL1 ↑ Cofilin 1 1.31
CAPN2 ↑ Calpain 2, (m/II) large subunit 1.28
SGK ↑ Serum/glucocorticoid regulated kinase 1.27
MIF ↑ Macrophage migration inhibitory factor 1.24
PEA15 ↑ Phosphoprotein enriched in astrocytes 15 1.23
MTCH1 ↑ Mitochondrial carrier homolog 1 1.08
Haemostasis, inflammation and 
immunity
PLAT ↑ Plasminogen activator, tissue 2.23
ENO1 ↑ Enolase 1 1.67
PTX3 ↑ Pentaxin-related gene 1.66
IFITM2 ↑ Interferon induced transmembrane protein 2 1.27
B2M ↑ Beta-2-microglobulin 1.26
ILF2 ↑ Interleukin enhancer binding factor 2 1.15
LBP ↓ Lipopolysaccharide binding protein -1.77
PTGDS ↓ Prostaglandin D2 synthase 21 kDa -1.14
AZU1 ↓ Azurocidin 1 -1.02
Stress/ubiquitination
ATOX1 ↑ ATX1 antioxidant protein 1 homolog 1.51
UCHL1 ↑ Ubiquitin carboxy-terminal esterase L1 1.33
ANAPC11 ↑ Anaphase promoting complex subunit 11 homolog 1.28
FTL ↑ Ferritin, light polypeptide 1.25
PMP22 ↑ Peripheral myelin protein 22 1.19
SLC38A2 ↑ Solute carrier family 38, member 2 1.14
PSMC1 ↑ Proteasome (prosome, macropain) 26S subunit, ATPase, 1 1.12
FKBP4 ↑ FK506 binding protein 4 1.12
PSMD13 ↑ Proteasome (prosome, macropain) 26S subunit, non-
ATPase, 13
1.03
PRDX1 ↑ Peroxiredoxin 1. 1.02
ANAPC10 ↓ Anaphase promoting complex subunit 10 -1.22
Transduction
Table 3 (Continued)
Class distribution of differentially expressed genes with a log odds ratio >1Available online http://arthritis-research.com/content/8/4/R115
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GJA1 ↑ Gap junction protein, alpha 1, 43 kDa (connexin 43) 1.39
HPCAL1 ↑ Hippocalcin-like 1 1.36
CFL1 ↑ Cofilin 1 1.31
RAC2 ↑ Ras-related C3 botulinum toxin substrate 2 1.30
SGK ↑ Serum/glucocorticoid regulated kinase 1.27
IL6ST ↑ Interleukin 6 signal transducer (gp130, oncostatin M 
receptor)
1.15
ARHGDIB ↑ Rho GDP dissociation inhibitor beta 1.10
GNG10 ↑ Guanine nucleotide binding protein, gamma 10 1.05
PRDX4 ↑ Peroxiredoxin 4 1.05
RHOA ↑ Ras homolog gene family, member A 1.02
PLXNB1 ↓ Plexin B1 -1.19
MAP4K1 ↓ Mitogen-activated protein kinase/kinase/kinase/kinase 1 -1.05
DNA/RNA organization
SBDS/CGI97 ↑ Shwachman-Bodian-Diamond syndrome 2.14
ENO1 ↑ Enolase 1 1.67
H3F3B ↑ H3 histone, family 3B 1.37
TRUB2 ↓ TruB pseudouridine synthase homolog 2 -1.23
AVPI1 ↓ Arginine vasopressin-induced 1 -1.12
C1orf34 ↓ Chromosome 1 open reading frame 34 -1.05
Transcription
BTF3L3 ↑ Basic transcription factor 3, like 3 1.21
ILF2 ↑ Interleukin enhancer binding factor 2 1.15
GATA6 ↓ GATA binding protein 6 -2.19
SOX9 ↓ SRY (sex determining region Y)-box 9 -1.99
RUNX2 ↓ Runt-related transcription factor 2 -1.16
NFAT5 ↓ Nuclear factor of activated T-cells 5 -1.14
SOX5P ↓ SRY (sex determining region Y)-box 5 -1.12
FOXA2 ↓ Forkhead box A2 -1.10
All genes with a log odds ratio >0 were considered significantly down-regulated (M < 0) or up-regulated (M > 0). The table reports only genes 
with M > 1 and M < 1. Upward and downward arrows indicate up- and down-regulation, respectively.
Table 3 (Continued)
Class distribution of differentially expressed genes with a log odds ratio >1Arthritis Research & Therapy    Vol 8 No 4    Giusti et al.
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Table 3, which reports differentially expressed genes with a
log odds ratio (LOR) >1.0 (see also Additional file 2), where
gene function was classified according to GO and to informa-
tion available in the NCBI web site and related links [29,30],
indicates that many genes that mediate endothelial cell migra-
tion/invasion, proliferation, cytoskeletal remodeling and capil-
lary differentiation (angiogenesis section) are up-regulated in
SSc-MVECs. However, the angiogenesis inhibitor pent(r)axin-
related gene (PTX3) is also up-regulated, while other genes
critical for the angiogenic process, such as plexin B1
(PLXNB1, semaphorin receptor), tissue kallikreins KLK9,
KLK11, and KLK12) [12], and DSG2 (a cadherin that medi-
ates homophilic cell adhesion), undergo down-regulation in
SSc-MVECs. Apoptosis-related genes (Table 3 and Addi-
tional file 3) were variously altered, including down-regulation
of BCL2 in SSc-MVECs, which also exhibited a general pro-
fibrinolytic pattern, coupled with over-expression of PTX3,
which increases tissue factor expression and stimulates gen-
eration of inflammation mediators, [31]. SSc-MVECs also
show up-regulation of genes related to a response to oxidative,
osmotic, and shear stress, and of genes linked with protein
ubiquitination and proteasoma activation (Table 3 and Addi-
tional file 4). Table 3 and Additional file 5 indicate an overall
perturbation of signal transductions mediated by small
GTPase proteins, and down-regulation of MAP4K in SSc-
MVECs, and of genes involved in nucleosome and chromatin
remodeling and in regulation of transcription, including down-
regulation of GATA6, which controls transcription of von Will-
ebrand factor, and of RUNX2, which controls endothelial cell
migration and invasion. Table 3 and additional file 6 show up-
regulation in SSc-MVECs of a large number of structural con-
stituents of ribosomes and of genes engaged in oxidative
phosphorylation and related ATP production, indicating an
intense protein synthesis and energy production in SSc-
MVECs. A series of 36 differentially expressed genes whose
functions are unknown or cannot be included within a class is
available as Additional file 7.
Validated expression of selected genes by RT-PCR
To validate the results of the cDNA microarray analysis, the
mRNA expression of nine selected genes was independently
examined with real time RT-PCR. We selected nine differen-
tially expressed transcripts, including many of those that are
functional to the main hypothesis of the present work (KLK9,
AF135026; KLK11, AB012917; KLK12, AF135025; IL8,
M17017; PLAU, X02419; PTX3, M31166; PLXNB1,
AJ011414; DSG2, NM_001943; CTGF, NM_001901);
among these were genes exhibiting a significant decrease
(KLK9, KLK11, KLK12, PLXNB1, and DSG2) or a significant
increase (IL8, PLAU, PTX3, and CTGF) in expression in SSc-
MVECs in comparison to N-MVECs. We evaluated these in
the same total RNAs used for comparative microarray experi-
ments. Real time RT-PCR analysis confirmed the data
obtained by microarray technology (Table 1). To reinforce the
data on the genes reported in Table 1, we also performed RT-
PCR determinations on single RNA preparations (from six SSc
patients and six healthy subjects), as previously described for
single KLKs [12]. The values obtained from these determina-
tions were similar to those obtained from the RNA pools: a
mean fold increase for PTX3 (1.72, range 1.18 to 4.73, p =
0.041), IL8 (3.3, range 1.51 to 7.9, p = 0.039), PLAU (2.76,
range 1.51 to 5.2, p = 0.02), and CTGF (1.79, range 1.19 to
3.09, p = 0.026); and a mean fold decrease for PLXNB1
(1.96, range 1.35 to 5.91, p = 0.042), DSG2 (29.91, range
10.62 to 68.9, p = 0.02), KLK9 (20.69, range 3.82 to 75.0, p
= 0.022), KLK11 (34.48, range 5.83 to 150.0, p = 0.021), and
KLK12 (24.26, range 2.64 to 118.0, p = 0.020).
Immunohistochemistry
On the basis of RT-PCR differential expression of the relevant
genes, we performed an immunohistochemistry analysis of the
nine validated molecules. In spite of the scarcity of microves-
sels in the lesional skin biopsies of SSc patients, all tissue
samples from both normal (six biopsies) and SSc (six biopsies)
subjects showed the presence of endothelial cells exhibiting
immunoreactivity for KLK9, KLK11, KLK12, DSG2, plexin B1,
IL8, PLAU, pent(r)axin 3, and connective tissue growth factor.
The sensitivity of the method did not enable us to identify a dif-
ferential immuno-staining for molecules whose RT-PCR
expression showed differences ranging from 42% (CTGF up-
regulation in SSc-MVECs, Table 1) to 185% (IL8 up-regula-
tion in SSc-MVECs, Table 1), while all the tissue KLKs and
DSG2, whose down-regulation in SSc-MVECs ranged from
10.63-fold to 53.07-fold, exhibited a measurable differential
staining (Figure 1). Due to the poor presence of microvessels
in SSc biopsies, an average of three vessels per biopsy was
subjected to image analysis. Evaluation of differential staining
intensity gave the following results: KLK9, 47.2 ± 15%
decrease in SSc (p < 0.05); KLK11, 69.7 ± 21% decrease in
SSc (p < 0.05); KLK12, 61.6 ± 23% decrease in SSc (p <
0.05); DSG2, 62.7 ± 14% decrease in SSc (p < 0.05). Iso-
type controls stained negative, as shown in the insets of Figure
1 (rabbit Ig G for KLK9 and KLK12, and mouse IgG for KLK9
and DSG).
Functional studies on the angiogenic effects of 
pentraxin 3, plexin B1 and DSG2
We have previously shown down-regulation at the protein level
of tissue KLK9, KLK11 and KLK12, as well as how such alter-
ations account for reduced angiogenesis in SSc-MVECs [12].
Here we have focused our studies on the role of pent(r)axin 3,
plexin B1, and DSG2, three gene products that are particularly
relevant to the hypothesis of the present study. Although the
90% decrease of PLXB1 and 58% increase of PTX3 mRNA in
SSc-MVECs (Table 1) were not demonstrable by differential
immuno-staining of endothelial cells in tissue biopsies, the dif-
ferential protein expression and their functional import were
evident by western blotting and in vitro angiogenesis assays.
Figures 2a, 3a and 4a, which show western blotting of cell
lysates with anti-plexin B1, anti-pent(r)axin 3 and anti-DSG2Available online http://arthritis-research.com/content/8/4/R115
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antibodies, respectively, indicate down-regulation of plexin B1
and DSG2, and up-regulation of pentraxin 3 in SSc-MVECs,
thereby confirming the microarray and RT-PCR data at the pro-
tein level. Figures 2b,c and 4b,c show that anti-plexin B1 and
anti-DSG2 antibodies (each used at 3 µg/ml), respectively,
were able to partially inhibit N-MVEC invasion through
Matrigel-coated porous filters, and exhibited a strong down-
regulation activity in capillary morphogenesis of N-MVECs.
Since pent(r)axin 3 was up-regulated in SSc-MVECs, we
added SSc-MVEC conditioned medium to N-MVECs for 24
hours, which resulted in a relevant inhibition of both invasion
(Figure 3b) and capillary morphogenesis (Figure 3c) of N-
MVECs. The effect of SSc-MVEC conditioned medium was
much reduced when added to N-MVECs in the presence of 3
µg/ml anti-pent(r)axin antibodies (Figure 3b,c). It is noteworthy
that anti-pent(r)axin antibodies exhibited a small inhibiting
activity on capillary morphogenesis of N-MVECs independent
of the presence of conditioned medium from SSc-MVEC cul-
tures.
Discussion
To date, this is the first study that compares the differential
transcriptosome of MVECs isolated from the skin of normal
subjects and from the lesional skin of SSc patients affected by
the diffuse form of the disease in the avascular phase.
The number of 6,724 genes that passed the filtering criteria is
in agreement with those previously obtained in other human
cell lines by microarray analysis [9] and by massively parallel
signature sequencing [32]. We have observed that the major-
ity of genes are expressed at similar levels in N-MVECs and
SSc-MVECs and that, interestingly, 3.2% of the total filtered
transcripts (199 genes) were differentially expressed. Consid-
ering the correctness of comparing data limited to transcripts,
we show that, in SSc-MVECs, the dysregulation involves only
a small number of genes controlling a large number of proc-
esses that are critical to the biology of endothelial cells.
Surprisingly, we have found that SSc-MVECs exhibit a pro-
angiogenic gene expression pattern (Table 3). In SSc, the ang-
iogenic process is severely impaired in the late phases of the
disease [33], independent of the increased levels of circulat-
ing Vascular Endothelial Growth Factor (VEGF) and FGF2
[34,35]. Therefore, it is likely that some critical checkpoints in
the control of angiogenesis are altered at the MVEC level. Our
data indicate down-regulation of PLXNB1, a receptor for sem-
aphorin that tracks the pathway to migrating endothelial cells
by activation of the MET oncogene and by stimulating Rho-ini-
tiated pathways [13,36,37], of tissue KLK9, KLK11 and
KLK12, shown to be required for MVEC migration and prolif-
eration [12], and of DSG2, which is positively involved in
homophilic cell-cell interaction [15,38]. At the same time,
PTX3, an angiogenesis inhibitor that acts by binding FGF2
[14], is up-regulated (Table 3). We propose to interpret these
data as a stabilization of a pro-angiogenic pattern dictated by
angiogenesis factors such as VEGF and FGF2 that is blocked
or rendered ineffective by the strong down-regulation of the
critical adhesion/invasion/proliferation systems and by up-reg-
ulation of the angiogenesis inhibitor PTX3 (Table 3). Due to a
common technical problem during the spotting procedure,
microarray data were not available for matrix metallo-protease-
12 (MMP12), which in a previous study on the same SSc-
MVECs was found to be up-regulated and responsible for
urokinase-type plasminogen activator receptor (uPAR) trunca-
tion and subsequent angiogenesis impairment [18]. In this pre-
vious work we suggested the possibility that the alterations we
observed in SSc-MVECs may initially be stimulated by environ-
ment factors and then become the product of the hypoxia-
Figure 1
Immunohistochemical evidence of differential expression of tissue kal- likrein (KLK)9, KLK11, KLK12, and DSG2 in microvascular endothelial  cells (MVECs) from normal subjects and patients with systemic sclero- sis (SSc) Immunohistochemical evidence of differential expression of tissue kal-
likrein (KLK)9, KLK11, KLK12, and DSG2 in microvascular endothelial 
cells (MVECs) from normal subjects and patients with systemic sclero-
sis (SSc). Each panel is representative of the pattern of immune stain-
ing with each antibody obtained for the six normal and six SSc patients 
subjected to skin biopsies from which MVECs were prepared. The 
inset in the micrograph of KLK12 shows negative staining using isotype 
control rabbit IgG (the isotype used for KLK9 and KLK12), while that 
shown in the micrograph of DSG shows negative staining for mouse 
IgG (the isotype used for KLK11 and DSG). Original magnification, 
200×.Arthritis Research & Therapy    Vol 8 No 4    Giusti et al.
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induced selection of an endothelial cell population more suita-
ble to survive in the hypoxic micro-environment typical of the
disease. Still, unexpectedly, in SSc-MVECs we have observed
an overall up-regulation of many components of several trans-
duction systems. The large majority of such alterations (Table
3, Additional file 5) deal with transduction by small GTPase
proteins, which couple signals from ECM molecules to the cell
cytoskeleton, inducing alternating states of cell contraction/
relaxation [39]. However, up-regulation of Rho GDP dissocia-
tion inhibitor beta (ARHGDIB) is likely to provide a critical 'bot-
tle-neck' to GTPase protein transductions by impairing the
substitution of GDP with GTP, thus preventing the receptor to
enter its activation state [40]. Also, PLXNB1 down-regulation
inhibits semaphorin-directed MVEC migration by blunting
Rho-initiated pathways [36,37]. Further, an overall impairment
to cell proliferation in SSc-MVECs must also be related to
down-regulation of MAP4K1, a serine/threonine kinase
involved in a variety of cellular signaling cascades [41].
Provided that all the observed alterations in gene expression
may be important in the pathogenesis of vascular damage in
SSc, our results allow the identification of some genes that
may block a correct angiogenesis program in SSc-MVECs. Of
particular interest may be genes involved in: MVEC migration,
proliferation and adhesion (down-regulated PLXNB1, KLKs,
DSG2); inhibition of angiogenesis (up-regulated PTX3); and
alteration of signal transduction pathways (up-regulated ARH-
GDIB, down-regulated PLXNB1, down-regulated MAP4K1)
Figure 2
Expression and role of plexin B1 (PLXNB1) in endothelial cell invasion and capillary morphogenesis Expression and role of plexin B1 (PLXNB1) in endothelial cell invasion and capillary morphogenesis. (a) Western blotting of 60 µg protein from cell 
lysates of microvascular endothelial cells (MVECs) from normal subjects (N-MVECs) and patients with systemic sclerosis (SSc-MVECs) with anti-
PLXNB1 antibodies. Each lane represents western blotting of MVECs obtained from a single patient. Actin was used as an internal reference stand-
ard. Numbers on the right represent the molecular weight expressed in kDa. (b) Effect of anti-PLXNB1 antibodies (3 µg/ml) on matrigel invasion of 
N-MVECs. The effect of irrelevant rabbit IgG is also shown. Numbers on the x-axis refer to the total number of cells migrated through the matrigel 
after 6 hours. Data are the mean ± standard deviation of three experiments performed in triplicate in three N-MVEC lines. The asterisk indicates that 
values are significantly different from the values of control (p < 0.05). (c) Effect of anti-PLXNB1 antibodies on capillary morphogenesis of N-MVECs. 
N-MVECs were plated on Matrigel (60 × 103/ml), in complete MCDB medium, supplemented with 30% fetal calf serum, and 20 µg/ml endothelial 
cells growth supplement. N-MVEC spontaneously form anastomosing cords of cells resembling a capillary plexus, which are well organized by 6 
hours. The process of endothelial cell organization after 6 hours is impaired in the presence of 3 µg/ml of anti-PLXNB1 rabbit polyclonal antibodies. 
Irrelevant rabbit IgG gave results similar to control untreated N-MVECs (not shown). These data are representative of three different experiments per-
formed on three N-MVEC cell lines (100× magnification). Numbers reported within each panel indicate the percent of the photographic field occu-
pied by cells ± standard deviation. The asterisk indicates that values are significantly different from the values of control N-MVECs at 6 hours after 
plating on Matrigel (p < 0.05).Available online http://arthritis-research.com/content/8/4/R115
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(Figure 5). For six of such genes (PLXNB1, PTX3, KLK9,
KLK11, KLK12, DSG2), we have provided evidence of a criti-
cal role in the angiogenic process (this work and [12]).
Over-expression of genes of proteasome and ubiquitin path-
ways suggests the possibility that the observed gene altera-
tions are the effect of a cell adaptation to a particularly hostile
environment. It is interesting to underline the induction of 3
metallothionein genes in SSc-MVECs. Metallothioneins
belong to a family of stress-induced proteins that regulate Zn
and Cu availability and also modulate the amount and activity
of NF-kB, a transcription factor for genes involved in apopto-
sis, immune response and inflammation [42].
Since RNA harvested from MVECs was obtained from cells
between the fourth and seventh passage, this could raise con-
cerns about MVEC stability and/or possible selection of cells
more likely to survive in culture. However, we previously
showed that RT-PCR, performed with RNA isolates of cells
from single patients at early and late culture passages to vali-
date tissue KLK expression, gave similar results, in agreement
with microarray data obtained with pooled RNA [12]. Moreo-
ver, the demonstration of down-regulation of KLK9, KLK11,
KLK12 and DSG2 in skin biopsies of SSc patients by immu-
nocytochemistry suggests that at least some of the reported
alterations pre-exist to the isolation and culture propagation
techniques. Nonetheless, a possible selection bias, responsi-
ble for some of the reported differences, cannot be ruled out.
Figure 3
Expression and role of pent(r)axin 3 (PTX3) in endothelial cell invasion and capillary morphogenesis Expression and role of pent(r)axin 3 (PTX3) in endothelial cell invasion and capillary morphogenesis. (a) Western blotting of 60 µg protein from cell 
lysates of microvascular endothelial cells (MVECs) from normal subjects (N-MVECs) and patients with systemic sclerosis (SSc-MVECs) with anti-
PTX3 antibodies. Each lane represents western blotting of MVECs obtained from a single patient. Actin was used as an internal reference standard. 
Numbers on the right represent the molecular weight expressed in kDa. (b) Effect of PTX3 antibodies (3 µg/ml) on matrigel invasion of N-MVECs. 
The effect of irrelevant rat IgG is also shown. Numbers on the x-axis refer to the total number of cells migrated through the matrigel after 6 hours. The 
presence of anti-PTX3 antibodies is able to revert inhibition of matrigel invasion induced by SSc-MVECs conditioned medium (C.M.). Data are the 
mean ± standard deviation of three experiments performed in triplicate in three N-MVEC lines. An asterisk indicates that values are significantly dif-
ferent from the values of control (p < 0.05). (c) Effect of anti-PTX3 antibodies on capillary morphogenesis of N-MVECs. Experimental conditions 
were as described in the legend to Figure 1. Conditioned medium from SSc-MVECs was able to impair capillary morphogenesis observed after 6 
hours from plating (panel c). The process of endothelial cell organization after 6 hours was partially restored in the presence of 3 µg/ml of anti-PTX3 
rat monoclonal antibodies (panel d), which showed only a small effect when added to control N-MVECs (panel b). Irrelevant rat IgG did not show any 
effect (not shown). These data are representative of three different experiments performed on three N-MVEC cell lines (100× magnification). Num-
bers reported within each panel indicate the percent of the photographic field occupied by cells ± standard deviation. An asterisk indicates that val-
ues are significantly different from the values of control N-MVECs at 6 hours after plating on Matrigel (p < 0.05).Arthritis Research & Therapy    Vol 8 No 4    Giusti et al.
Page 14 of 17
(page number not for citation purposes)
There is evidence that inference from most genes is not
adversely affected by pooling, such that pooling is recom-
mended when fewer than three arrays are used in each condi-
tion [43]. Additionally, due to the small number of replicates,
we decided to apply the dye swap design to minimize the
gene-specific dye bias [44], which is the major source of
experimental variability between replicates. In the present
study we have applied markedly stringent criteria for feature
extraction and data normalization, which could blunt the iden-
tification of differentially expressed genes. Nevertheless, we
believe that our findings, related to single genes, or classes of
genes, may provide hints for future research and are worthy of
a more in-depth study to identify possible ways to correct
some critical molecular defects and to recover, at least par-
tially, the angiogenic attitude of SSc-MVECs.
Conclusion
In this study we analyzed gene expression profiles of skin
MVECs isolated from healthy subjects and diffuse SSc
patients, using a microarray approach and validating data on a
series of selected genes by quantitative RT-PCR. Based on
gene ontology and other classification criteria, we found that
SSc-MVECs, while being unable to perform angiogenesis,
over-express a large variety of transcripts positively involved in
angiogenesis. However, such a pro-angiogenic pattern of
SSc-MVECs is counterbalanced by up-regulation of
pent(r)axin 3, a powerful angiogenesis inhibitor, by down-reg-
ulation of a few critical pro-angiogenic transcripts (three tissue
KLKs, plexin-B1, and DSG), and by alteration of transcripts
involved in signal transduction pathways. This different expres-
sion profile and identification of a few molecules able to
Figure 4
Expression and role of desmoglein (DSG)2 in endothelial cell invasion and capillary morphogenesis Expression and role of desmoglein (DSG)2 in endothelial cell invasion and capillary morphogenesis. (a) Western blotting of 60 µg protein from cell 
lysates of microvascular endothelial cells (MVECs) from normal subjects (N-MVECs) and patients with systemic sclerosis (SSc-MVECs) with anti-
DSG2 antibodies. Each lane represents western blotting of MVECs obtained from a single patient. Actin was used as an internal reference standard. 
Numbers on the right represent the molecular weight expressed in kDa. (b) Effect of anti-DSG2 antibodies (3 µg/ml) on matrigel invasion of N-
MVECs. The effect of irrelevant mouse IgG is also shown. Numbers on the x-axis refer to the total number of cells migrated through the matrigel after 
6 hours. Data are the mean ± standard deviation of three experiments performed in triplicate in three N-MVEC lines. The asterisk indicates that val-
ues are significantly different from the values of control (p < 0.05). (c) Effect of anti-DSG2 antibodies on capillary morphogenesis of N-MVECs. See 
the legend to Figure 1 for experimental details. Irrelevant mouse IgG gave results similar to control untreated N-MVECs (not shown). These data are 
representative of three different experiments performed on three N-MVEC cell lines (100× magnification). Numbers reported within each panel indi-
cate the percent of the photographic field occupied by cells ± standard deviation. The asterisk indicates that values are significantly different from 
the values of control N-MVECs at 6 hours after plating on Matrigel (p < 0.05).Available online http://arthritis-research.com/content/8/4/R115
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account for impaired angiogenesis in SSc provide the focus
for future attempts to correct anti-angiogenesis in SSc.
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